

# Rashmi K Murthy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2443917/publications.pdf>

Version: 2024-02-01

36  
papers

2,857  
citations

394421

19  
h-index

377865

34  
g-index

37  
all docs

37  
docs citations

37  
times ranked

3456  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 597-609.	27.0	789
2	Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low Expressing Advanced Breast Cancer: Results From a Phase Ib Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 1887-1896.	1.6	465
3	Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. <i>Lancet Oncology</i> , The, 2019, 20, 816-826.	10.7	252
4	Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 2033-2041.	7.0	224
5	Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 509.	7.1	154
6	Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. <i>Lancet Oncology</i> , The, 2018, 19, 880-888.	10.7	144
7	Phase I Study of ONT-380, a HER2 Inhibitor, in Patients with HER2+ Advanced Solid Tumors, with an Expansion Cohort in HER2+ Metastatic Breast Cancer (MBC). <i>Clinical Cancer Research</i> , 2017, 23, 3529-3536.	7.0	112
8	Outcomes of children exposed in utero to chemotherapy for breast cancer. <i>Breast Cancer Research</i> , 2014, 16, 500.	5.0	75
9	Distress and quality of life in primary high-grade brain tumor patients. <i>Supportive Care in Cancer</i> , 2009, 17, 793-799.	2.2	71
10	T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2 Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab. <i>Journal of Clinical Oncology</i> , 2016, 34, 3511-3517.	1.6	64
11	Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2515-2523.	7.0	58
12	SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 16.	5.2	48
13	Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. <i>Oncologist</i> , 2018, 23, 1300-1309.	3.7	46
14	Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 1654.	7.1	42
15	Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy. <i>Oncologist</i> , 2019, 24, 313-318.	3.7	39
16	Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2 positive metastatic breast cancer. <i>Cancer</i> , 2014, 120, 1932-1938.	4.1	35
17	An open-label, phase 2 trial of RPI.4610 (angiozyme) in the treatment of metastatic breast cancer. <i>Cancer</i> , 2012, 118, 4098-4104.	4.1	33
18	Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 6354-6365.	7.0	31

#	ARTICLE	IF	CITATIONS
19	A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. <i>British Journal of Cancer</i> , 2019, 120, 1105-1112.	6.4	22
20	Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer. <i>Clinical Immunology</i> , 2021, 225, 108679.	3.2	19
21	Initial safety analysis of a randomized phase II trial of nelipepimut-S+GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors. <i>Clinical Immunology</i> , 2019, 201, 48-54.	3.2	17
22	A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. <i>Investigational New Drugs</i> , 2018, 36, 299-306.	2.6	16
23	Genetic Counseling Referral Rates in Long-Term Survivors of Triple-Negative Breast Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 518-524.	4.9	14
24	A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR- $\beta$ . <i>Investigational New Drugs</i> , 2018, 36, 1103-1109.	2.6	13
25	Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1). <i>Breast Cancer Research and Treatment</i> , 2019, 176, 227-234.	2.5	13
26	FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036. <i>Npj Breast Cancer</i> , 2021, 7, 51.	5.2	11
27	Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. <i>Clinical Breast Cancer</i> , 2018, 18, e1283-e1288.	2.4	10
28	Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer. <i>JCO Clinical Cancer Informatics</i> , 2021, 5, 789-804.	2.1	10
29	Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2878-2889.	7.0	10
30	Bone biology and the role of the RANK ligand pathway. <i>Oncology</i> , 2009, 23, 9-15.	0.5	6
31	Adjuvant HER2-Targeted Therapy Update in Breast Cancer: Escalation and De-escalation of Therapy in 2018. <i>Current Breast Cancer Reports</i> , 2018, 10, 296-306.	1.0	5
32	Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 1323.	3.7	4
33	Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab. <i>Oncologist</i> , 2020, 25, e909-e919.	3.7	2
34	Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice. <i>Npj Breast Cancer</i> , 2020, 6, 11.	5.2	2
35	Reply to T.J.A. Dekker. <i>Journal of Clinical Oncology</i> , 2020, 38, 3351-3352.	1.6	0
36	Reply to A. Pfob and C. Sidey-Gibbons. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100171.	2.1	0